NFKB1 and primary cutaneous T-cell non-Hodgkin lymphoma: Constitutive activation of the transcription factor nuclear factor kappa B (NFκB) has been confirmed in CTCL, with NF-kB activation associated with resistance to cell death, potentially explaining treatment failure.